Urinary tract infections (UTIs) are a significant public health issue, caused primarily by bacteria such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. UTIs can be categorized as uncomplicated or complicated, with complicated infections often associated with factors like indwelling catheters, urinary tract abnormalities, or immunosuppression. These infections are associated with high recurrence rates and increasing antimicrobial resistance, leading to significant economic and health burdens. The molecular mechanisms of UTI pathogenesis involve host-pathogen interactions, including bacterial adhesion, colonization, and biofilm formation. Uropathogens use various virulence factors, such as adhesins, pili, and toxins, to invade host tissues, evade immune responses, and persist in the urinary tract. Understanding these mechanisms is crucial for developing new treatments, including antivirulence therapies that target pathogenic processes without disrupting normal microbiota. Current research focuses on translating basic science findings into clinical treatments, including vaccines and small molecules targeting virulence factors. Multidrug-resistant uropathogens pose a growing challenge, necessitating the development of alternative therapies, such as combination therapies with beta-lactamase inhibitors, and vaccines targeting bacterial adhesion. The emergence of resistance mechanisms, such as extended-spectrum beta-lactamases (ESBLs) and carbapenemases, highlights the need for innovative approaches to combat UTIs effectively.Urinary tract infections (UTIs) are a significant public health issue, caused primarily by bacteria such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. UTIs can be categorized as uncomplicated or complicated, with complicated infections often associated with factors like indwelling catheters, urinary tract abnormalities, or immunosuppression. These infections are associated with high recurrence rates and increasing antimicrobial resistance, leading to significant economic and health burdens. The molecular mechanisms of UTI pathogenesis involve host-pathogen interactions, including bacterial adhesion, colonization, and biofilm formation. Uropathogens use various virulence factors, such as adhesins, pili, and toxins, to invade host tissues, evade immune responses, and persist in the urinary tract. Understanding these mechanisms is crucial for developing new treatments, including antivirulence therapies that target pathogenic processes without disrupting normal microbiota. Current research focuses on translating basic science findings into clinical treatments, including vaccines and small molecules targeting virulence factors. Multidrug-resistant uropathogens pose a growing challenge, necessitating the development of alternative therapies, such as combination therapies with beta-lactamase inhibitors, and vaccines targeting bacterial adhesion. The emergence of resistance mechanisms, such as extended-spectrum beta-lactamases (ESBLs) and carbapenemases, highlights the need for innovative approaches to combat UTIs effectively.